

Bayer buys Cambridge cell therapy startup BlueRock at \$1B value



The Bayer Cross at night
BAYER AG

IN THIS ARTICLE

By **Allison DeAngelis** – Life Sciences Reporter, Boston Business Journal

Aug 8, 2019, 10:09am

Biotech

Topic

EDT **Updated** Aug 8, 2019, 4:25pm EDT

BlueRock

Therapeutics

Company

Health

Care

Industry

More

The German-based drug giant has doubled down on one of its previous investments, announcing a deal to acquire the remainder of the stake in BlueRock Therapeutics for \$600 million.